GLPG

Galapagos NV

Add to Watchlist

Advanced Chart

32.560

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

32.560

Open

32.560

VWAP

32.56

Vol

12.18K

Mkt Cap

2.15B

Low

32.560

Amount

396.61K

EV/EBITDA(TTM)

Total Shares

65.90M

-1.24B

EV/OCF(TTM)

P/S(TTM)

3.42

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

69.08M

+15.43%

70.04M

-7.22%

68.21M

-9.03%

Estimates Revision

The market is revising No Change the revenue expectations for Galapagos NV (GLPG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 29.88%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+29.88%

In Past 3 Month

4 Analyst Rating

-20.15% Downside

Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 26.00 USD with a low forecast of 22.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

1 Sell

Hold

-20.15% Downside

Current: 32.560

Low

22.00

Averages

26.00

High

29.00

-20.15% Downside

Current: 32.560

Low

22.00

Averages

26.00

High

29.00

Deutsche Bank

Hold

Sell

downgrade

€19

2025-08-05

Reason

Deutsche Bank

Price Target

€19

2025-08-05

downgrade

Hold

Sell

Reason

Deutsche Bank downgraded Galapagos to Sell from Hold with a EUR 19 price target.

Deutsche Bank

Hold

Sell

downgrade

2025-08-05

Reason

Deutsche Bank

Price Target

2025-08-05

downgrade

Hold

Sell

Reason

Deutsche Bank downgraded Galapagos to Sell from Hold with a price target of EUR 19, down from EUR 22, after the company decided to drop their cash guidance for FY25 along with the company's Q2 earnings report, stating that a strategy review is required to develop a better understanding of the cash runway going forward. The firm cites the removal of the cash guidance, uncertainty around the company's structure and risks around future business development and current cell therapy programs for its downgrade.

Morgan Stanley

Judah Frommer

Hold

Sell

Downgrades

$31 → $22

2025-02-14

Reason

Morgan Stanley

Judah Frommer

Price Target

$31 → $22

2025-02-14

Downgrades

Hold

Sell

Reason

Morgan Stanley downgraded Galapagos to Underweight from Equal Weight with a price target of $22, down from $33.

Barclays

Emily Field

Hold

Sell

Downgrades

n/a

2025-01-23

Reason

Barclays

Emily Field

Price Target

n/a

2025-01-23

Downgrades

Hold

Sell

Reason

Barclays downgraded Galapagos to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos' ongoing spin process not expected to complete until the middle of this year, a takeover is unlikely for the time being, the analyst tells investors in a research note. The firm is not expecting any major clinical data in the first half of 2025, which it thinks will keep "a lid on shares for the time being."

RBC Capital

Brian Abrahams

Hold

Maintains

$32 → $30

2024-11-01

Reason

RBC Capital

Brian Abrahams

Price Target

$32 → $30

2024-11-01

Maintains

Hold

Reason

Leerink Partners

Faisal Khurshid

Hold

Initiates

$24

2024-09-09

Reason

Leerink Partners

Faisal Khurshid

Price Target

$24

2024-09-09

Initiates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Galapagos NV (GLPG.O) is -21.25, compared to its 5-year average forward P/E of -6.58. For a more detailed relative valuation and DCF analysis to assess Galapagos NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.58

Current PE

-21.25

Overvalued PE

92.43

Undervalued PE

-105.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

9.81

Current EV/EBITDA

5.71

Overvalued EV/EBITDA

18.37

Undervalued EV/EBITDA

1.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.47

Current PS

6.69

Overvalued PS

9.81

Undervalued PS

5.13

Financials

Annual

Quarterly

FY2025Q2

YoY :

-23.30%

65.29M

Total Revenue

FY2025Q2

YoY :

+49.36%

-57.03M

Operating Profit

FY2025Q2

YoY :

-2340.94%

-104.45M

Net Income after Tax

FY2025Q2

YoY :

-1242.86%

-1.60

EPS - Diluted

FY2025Q2

YoY :

-38.47%

-78.37M

Free Cash Flow

FY2025Q2

YoY :

+15.20%

92.79

Gross Profit Margin - %

FY2025Q2

YoY :

-46.56%

-91.01

FCF Margin - %

FY2025Q2

YoY :

-3019.34%

-159.98

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 32620.27% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

154.7K

Volume

6-9

Months

6.9M

Volume

0-12

Months

0.0

Volume

Bought

0-3

7.7M

Volume

Months

3-6

23.4K

Volume

Months

6-9

39.0K

Volume

Months

0-12

37.5K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

GLPG News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

05:28:08

Galapagos granted RMAT designation to GLPG5101 by FDA

2025-06-23 (ET)

2025-06-23

05:11:08

Galapagos CFO Thad Huston to depart, Aaron Cox to succeed

2025-06-18 (ET)

2025-06-18

16:07:16

Galapagos presents new data from ATALANTA-1 trial

News

9.0

08-06Newsfilter

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

9.5

07-24Benzinga

Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

9.5

07-24Benzinga

Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket